Company Analysis

UroGen Pharma Ltd. (URGN)

Nasdaq: URGN · Pharmaceutical Preparations · Ra'Anana, IL · filing with the SEC since 2016
Grade5.2
◀ Past 5.1● Present 5.5▶ Future 4.8
1 est.

Who runs UroGen Pharma Ltd.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Barrett Elizabeth A.
Chief Executive Officer. First filing Jan 2019, latest Feb 19, 2026, 6 filings in all.
Officers reporting now
4
of 10 people with a filing in the last fifteen months
Directors reporting now
6
19 people on the record since 2017
Officerssales are open-market, Oct 9, 2025 to Oct 9, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Degnan ChrisChief Financial OfficerOct 2024Oct 9, 20261 · $100,000
Schoenberg MarkChief Medical OfficerJan 2019Sep 9, 202610 · $4.5M
Smith Jason DrewGeneral CounselSep 2020Sep 9, 20264 · $200,000
Barrett Elizabeth A.Chief Executive OfficerJan 2019Feb 19, 2026none
Directorssales are open-market, Oct 9, 2025 to Oct 9, 2026
NameRoleFirst filingLatest filingSales, 12 months
Robinson James A. Jr.directorJul 2023Aug 28, 2026none
Belldegrun AriedirectorJan 2019Jun 24, 2026none
Butitta Cynthia MdirectorJan 2019Jun 24, 2026none
Holden StuartdirectorJan 2019Jun 24, 2026none
Wen LeanadirectorSep 2022Jun 24, 2026none
Wildman Daniel GeorgedirectorNov 2022Jun 24, 2026none
Earlier names on the record13, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton URGN · research, not advice